DelveInsight's "Pulmonary Hypertension Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Pulmonary Hypertension market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers the emerging Pulmonary Hypertension drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Pulmonary Hypertension treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Pulmonary Hypertension: An Overview
Pulmonary hypertension, or PH, occurs when blood pressure within the lungs becomes abnormally elevated. It can be caused by a thickening of the pulmonary artery walls, heart failure, lung disease (such as interstitial lung disease), and clots within the lungs' blood vessels. It is an important complication of several interstitial lung diseases (ILDs) and can adversely affect patient outcomes.
Pulmonary hypertension has many different causes. It is usually a complication of heart disease or lung disease. But many other diseases and environmental factors can raise your risk for PH. The treatment management of pulmonary hypertension associated with interstitial lung disease is a bit complex as it is an association of two diseases. The treatment involves the management of the underlying lung disease and vasomodulation therapy, which is known to be effective against pulmonary hypertension.
Pulmonary Hypertension Market Key Facts
-
As per DelveInsight’s analysts, within PH, the US accounted for 29,925 total diagnosed prevalent cases of PAH (Group I) in 2019 and these cases are expected to increase during the forecast period.
-
Within pulmonary hypertension, the highest share of cases is estimated to be attributed to pulmonary hypertension due to heart disease.
-
According to the British Heart Foundation (BHF) (2022), pulmonary hypertension is a common complication of heart failure but rarely occurs spontaneously in people who do not have any other known cause of the disease, when it is known as PAH. This spontaneous or idiopathic form of the disease affects about 6,500 people in the UK.
-
According to Wijeratne et al. (2018), the annual prevalence of adult PH from 1993 to 2012 increased from 99.8 to 127.3 cases/100 000 population, respectively. The most common form of adult PH was group 2, or combined with group 3 PH.
The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Pulmonary Hypertension market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Pulmonary Hypertension market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Pulmonary Hypertension Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Pulmonary Hypertension epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Pulmonary Hypertension Epidemiology, Segmented as -
-
Total Diagnosed Prevalence of Pulmonary Hypertension (PH) in the 7MM [2019-2032]
-
Class-specific Diagnosed Prevalence of Pulmonary Hypertension (PH) in the 7MM [2019-2032]
-
Gender-specific Diagnosed Prevalence of Pulmonary Hypertension (PH) in the 7MM [2019-2032]
-
Treated Diagnosed cases of Pulmonary Hypertension (PH) in the 7MM [2019-2032]
Pulmonary Hypertension Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Pulmonary Hypertension market or expected to be launched during the study period. The analysis covers the Pulmonary Hypertension market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the Pulmonary Hypertension market drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the Pulmonary Hypertension drugs based on their sale and market share.
The report also covers the Pulmonary Hypertension pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Pulmonary Hypertension Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/pulmonary-hypertension-market
Pulmonary Hypertension Therapeutics Analysis
Several major pharma and biotech companies are developing therapies for Pulmonary Hypertension. Currently, Akaza Bioscience is leading the therapeutics market with its Pulmonary Hypertension drug candidates in the most advanced stage of clinical development.
Pulmonary Hypertension Companies Actively Working in the Therapeutics Market Include
Reata Pharmaceuticals, Pharmosa BioPharm, United Therapeutics Corporation, Acceleron Pharma, Bellerophon Therapeutics, Dong-A ST/Mezzion, Northern Therapeutics, Merck Sharp & Dohme Corp., Apeiron Biologics, VIVUS, Respira Therapeutics, Resverlogix, Bial - Portela C S.A., Vigonvita Life Sciences, Altavant Sciences, Roche, PhaseBio Pharmaceuticals, Gossamer Bio, Reviva Biopharmaceuticals, Cereno Scientific, Attgeno, Rho Federal Systems Division, Inc., Cumberland Pharmaceuticals, AstraZeneca, Aerovate Therapeutics, Celon Pharma, Camurus, ATXA Therapeutics, Gmax Biopharma, Aerami Therapeutics, Pfizer, Aadi Biosciences, SystImmune, Claritas Pharmaceuticals, Reviva Biopharmaceuticals, Aqualung Therapeutics, Pulmokine, and many others.
Emerging and Marketed Pulmonary Hypertension Therapies Covered in the Report Include:
-
Ralinepag: Arena Pharmaceuticals/United Therapeutics
-
Sotatercept: Acceleron Pharma
-
Zamicastat: Bial - Portela C S.A.
-
Tocilizumab: Roche
-
AER-901: Aerami Therapeutics
-
ABI-009: Aadi Biosciences
-
RT234: Respira Therapeutics
-
GMA 301: Gmax Biopharma
-
Zamicastat: Bial Portela CSA
-
Treprostinil Palmitil Inhalation Powder: Insmed, Inc.
And Many More
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
https://www.delveinsight.com/sample-request/pulmonary-hypertension-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Pulmonary Hypertension Competitive Intelligence Analysis
4. Pulmonary Hypertension Market Overview at a Glance
5. Pulmonary Hypertension Disease Background and Overview
6. Pulmonary Hypertension Patient Journey
7. Pulmonary Hypertension Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Pulmonary Hypertension Treatment Algorithm, Current Treatment, and Medical Practices
9. Pulmonary Hypertension Unmet Needs
10. Key Endpoints of Pulmonary Hypertension Treatment
11. Pulmonary Hypertension Marketed Therapies
12. Pulmonary Hypertension Emerging Drugs and Latest Therapeutic Advances
13. Pulmonary Hypertension Seven Major Market Analysis
14. Attribute Analysis
15. Pulmonary Hypertension Market Outlook (In US, EU5, and Japan)
16. Pulmonary Hypertension Access and Reimbursement Overview
17. KOL Views on the Pulmonary Hypertension Market
18. Pulmonary Hypertension Market Drivers
19. Pulmonary Hypertension Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/pulmonary-hypertension-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
"Nephrosclerosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Nephrosclerosis market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Nephrosclerosis market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email:Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
